Association between chitinase-3-like protein 1 and metabolic-associated fatty liver disease in patients with type 2 diabetes mellitus. 2024

Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
Department of Endocrinology, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.

OBJECTIVE Early identification of liver fibrosis is essential for the prognosis of metabolic-associated fatty liver disease (MAFLD), particularly in type 2 diabetes mellitus (T2DM) patients. Here, we explored the association of chitinase-3-like protein 1 (CHI3L1) and liver fibrosis in T2DM-MAFLD patients. METHODS Liver fibrosis was staged in T2DM-MAFLD patients, and a liver stiffness measurement (LSM) of ≥ 8 kPa was used to differentiate between non-significant (NSLF) and significant liver fibrosis (SLF) subgroups. The two subgroups were compared for serum CHI3L1 and other parameters. Linear correlation, logistic regression, and restricted cubic spline (RCS) analyses were performed to evaluate the association between CHI3L1 and liver fibrosis. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic accuracy of CHI3L1. RESULTS Among T2DM-MAFLD, SLF patients had higher CHI3L1 compared to NSLF patients. CHI3L1 was found to be positively correlated with LSM. Multivariate logistic regression analysis suggested that CHI3L1 may be a potential independent risk factor for SLF. Further stratified analysis indicated that the odds ratios of SLF in the high CHI3L1 group were higher than in the low CHI3L1 group in the subgroups. RCS analysis suggested an increasing trend in the incidence of significant fibrosis with the rising level of CHI3L1. The area under the ROC curve for detecting significant fibrosis was 0.749 (95% CI: 0.668-0.829). CONCLUSIONS Serum CHI3L1 demonstrates an association with significant liver fibrosis. High serum levels of CHI3L1 may indicate the existence of significant liver fibrosis in T2DM-MAFLD patients.

UI MeSH Term Description Entries

Related Publications

Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
January 2022, Frontiers in endocrinology,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
January 2023, Annals of hepatology,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
September 2011, Medical ultrasonography,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
March 2023, Diabetes & metabolism,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
November 2023, Diabetes & metabolism,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
January 2020, International journal of medical sciences,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
January 2022, Frontiers in public health,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
January 2023, Frontiers in endocrinology,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
January 2019, PeerJ,
Fan Zhang, and Yan Han, and Liming Zheng, and Zuowei Bao, and Longgen Liu, and Wenjian Li
January 2023, Diabetes, metabolic syndrome and obesity : targets and therapy,
Copied contents to your clipboard!